BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16735117)

  • 1. Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.
    Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Moskey MD; Pease LJ; Stewart KD; Yates M; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4326-30. PubMed ID: 16735117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
    Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
    Cao H; Zhang H; Zheng X; Gao D
    J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.
    Hamby JM; Connolly CJ; Schroeder MC; Winters RT; Showalter HD; Panek RL; Major TC; Olsewski B; Ryan MJ; Dahring T; Lu GH; Keiser J; Amar A; Shen C; Kraker AJ; Slintak V; Nelson JM; Fry DW; Bradford L; Hallak H; Doherty AM
    J Med Chem; 1997 Jul; 40(15):2296-303. PubMed ID: 9240345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Traceless solid-phase synthesis of 2-aminothiazoles: receptor tyrosine kinase inhibitors with dual selectivity for Tie-2 and VEGFR-2.
    Stieber F; Mazitschek R; Soric N; Giannis A; Waldmann H
    Angew Chem Int Ed Engl; 2002 Dec; 41(24):4757-61. PubMed ID: 12481350
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
    Kissau L; Stahl P; Mazitschek R; Giannis A; Waldmann H
    J Med Chem; 2003 Jul; 46(14):2917-31. PubMed ID: 12825933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors.
    Becknell NC; Zulli AL; Angeles TS; Yang S; Albom MS; Aimone LD; Robinson C; Chang H; Hudkins RL
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5368-72. PubMed ID: 16890434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
    Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Piatnitski E; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2006 Feb; 16(3):602-6. PubMed ID: 16275072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E; Ouyang S
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1440-4. PubMed ID: 16321531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.
    Miyazaki Y; Matsunaga S; Tang J; Maeda Y; Nakano M; Philippe RJ; Shibahara M; Liu W; Sato H; Wang L; Nolte RT
    Bioorg Med Chem Lett; 2005 May; 15(9):2203-7. PubMed ID: 15837294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
    Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
    J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
    Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
    J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
    Renhowe PA; Pecchi S; Shafer CM; Machajewski TD; Jazan EM; Taylor C; Antonios-McCrea W; McBride CM; Frazier K; Wiesmann M; Lapointe GR; Feucht PH; Warne RL; Heise CC; Menezes D; Aardalen K; Ye H; He M; Le V; Vora J; Jansen JM; Wernette-Hammond ME; Harris AL
    J Med Chem; 2009 Jan; 52(2):278-92. PubMed ID: 19113866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors.
    McBride CM; Renhowe PA; Gesner TG; Jansen JM; Lin J; Ma S; Zhou Y; Shafer CM
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3789-92. PubMed ID: 16678414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines.
    Hubbard RD; Dickerson SH; Emerson HK; Griffin RJ; Reno MJ; Hornberger KR; Rusnak DW; Wood ER; Uehling DE; Waterson AG
    Bioorg Med Chem Lett; 2008 Nov; 18(21):5738-40. PubMed ID: 18842405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
    Garofalo A; Goossens L; Six P; Lemoine A; Ravez S; Farce A; Depreux P
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2106-12. PubMed ID: 21353546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.